3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
25
Phase 3
6
Phase NA
2
Phase 4
1
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor
1
Interventions
Cyclophosphamide
250
Radiotherapy
172
pembrolizumab
154
Carboplatin
146
Gemcitabine
139
Nivolumab
135
Paclitaxel
129
Dexamethasone
118
Cisplatin
118
fludarabine
115
Rituximab
104
Lenalidomide
103
Bevacizumab
99
Docetaxel
97
Capecitabine
97
fludarabine phosphate
92
Temozolomide
89
Cytarabine
89
Oxaliplatin
87
Etoposide
82
Filgrastim
77
Irinotecan
73
Doxorubicin
73
venetoclax
70
Peripheral Blood Stem Cell Transplantation
68
Fluorouracil
68
Radiosurgery
66
Melphalan
66
Everolimus
66
Bortezomib
66
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
OTHER
×
aumolertinib
×
Clear all
NCT06947811
2025-06-04
APEAK
Sun Yat-sen University
Phase 1/2
Recruiting
71 enrolled